|
Harbour BioMed, a global biopharmaceutical company, announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody (HBM4003) in combination therapy with toripalimab (anti-PD-1 antibody) for patients suffering from advanced melanoma and other solid tumours.
As the first heavy chain only fully-human antibody on clinical stage in the world, HBM4003 showed its good safety profile and strong efficacy on its monotherapy study of phase I trial. HBM is making all efforts to push forward to the studies of this product in combination therapy as treatment for multiple solid tumours, including melanoma, NSCLC, HCC, NET/NEC.
HBM4003 is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, HBM4003 has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumour tissues. The potent anti-tumour efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favourable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.
Harbour BioMed is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology.
|